Newly Emerging Immunotherapy for Pancreatic Cancer Treatment - Trial NCT06370754
Access comprehensive clinical trial information for NCT06370754 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Fudan University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 117 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fudan University
Timeline & Enrollment
Phase 1/2
Apr 30, 2024
Apr 30, 2027
Primary Outcome
Incidence of dose-limiting toxicity (DLT) (phase IB),Objective Response Rate (ORR) (phase II)
Summary
This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of
 different novel immunotherapies in patients with advanced pancreatic cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06370754
Non-Device Trial